IceCure Medical Ltd (NASDAQ:ICCM – Get Rating) – Analysts at Brookline Capital Management reduced their FY2026 earnings per share (EPS) estimates for shares of IceCure Medical in a report released on Friday, December 30th. Brookline Capital Management analyst K. Dolliver now anticipates that the company will post earnings per share of $0.03 for the year, down from their previous forecast of $0.04. The consensus estimate for IceCure Medical's current full-year earnings is ($0.42) per share.
Get IceCure Medical alerts:Separately, Maxim Group began coverage on shares of IceCure Medical in a report on Tuesday, October 25th. They issued a "buy" rating and a $3.00 target price on the stock.
IceCure Medical Trading Up 5.4 %
IceCure Medical stock opened at $1.55 on Monday. IceCure Medical has a 52-week low of $0.75 and a 52-week high of $4.73. The business has a 50-day simple moving average of $1.18 and a two-hundred day simple moving average of $1.45. The company has a market cap of $70.72 million, a P/E ratio of -3.44 and a beta of 0.33. The company has a quick ratio of 3.58, a current ratio of 4.22 and a debt-to-equity ratio of 0.03.IceCure Medical (NASDAQ:ICCM – Get Rating) last posted its earnings results on Monday, December 5th. The company reported ($0.11) EPS for the quarter, hitting the consensus estimate of ($0.11). IceCure Medical had a negative net margin of 462.46% and a negative return on equity of 77.00%.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in IceCure Medical stock. JPMorgan Chase & Co. bought a new stake in IceCure Medical Ltd (NASDAQ:ICCM – Get Rating) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 7,240 shares of the company's stock, valued at approximately $78,000.
About IceCure Medical
(Get Rating)
IceCure Medical Ltd, a medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a cryoablation solution for the treatment of breast tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.
Featured Articles
- Get a free copy of the StockNews.com research report on IceCure Medical (ICCM)
- MarketBeat: Week in Review 12/26 – 12/30
- The Dogs Of Tech: It's Time For A Bite Of These Stocks
- Does This Acquisition Make Microsoft a Bear Market Buy?
- Should You Warm up to Generac Stock for the Winter?
- Is Kintara Therapeutics A Hidden Gem?
Receive News & Ratings for IceCure Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IceCure Medical and related companies with MarketBeat.com's FREE daily email newsletter.